A simeprevir (SMV)-based regimen has shown promising results in treating chronic hepatitis C virus (HCV) infection. This meta-analysis aimed to assess the efficacy and safety of simeprevir for treating HCV genotype 1 infection.
INTRODUCTION
Hepatitis C virus (HCV) infection still carries a major global health burden. It is estimated that ~160 million individuals, i.e. 2.35% of the world population, are chronically infected with HCV and ~350,000 people die from HCV-related cirrhosis and liver cancer each year (1) (2) (3) (4) .
The past two decades have witnessed progressive improvements in the sustained virologic response (SVR) rate, initially with peginterferon and ribavirin (PegIFN/ RBV), and the later addition of telaprevir or boceprevir (3) (4) (5) (6) (7) (8) . However, all these combination or triple therapies often cause frequent and severe adverse events (AEs) and increase the complexity of these treatments (9) (10) (11) . Recently, several all-oral combination trials (12) (13) (14) (15) (16) with different direct-acting antiviral agents (DAAs) have shown high SVR rates, excellent tolerability, and shortened treatment duration in the US, EU and other developed countries, but PegIFN-based treatment is still widely used in most developing countries (17) .
Simeprevir (SMV, TMC435) is an oral NS3/4A HCV protease inhibitor with activity against all HCV genotypes except genotype 3 (18, 19) . It has been approved in several countries as a triple regimen (SMV/PegIFN/RBV) for chronic HCV infection (19, 20) . Recently, a pooled safety analysis of five phase IIb and III randomized controlled trials (RCTs) (21) demonstrated that the addition of SMV to PegIFN/RBV is well tolerated in patients infected with HCV genotype 1. However, the efficacy of SMV was not addressed in the analysis.
Therefore, we performed a meta-analysis of all available RCTs to provide a comprehensive evaluation of the efficacy and safety of addition of SMV to the PegIFN/RBV regimen in patients with chronic HCV genotype 1 infection, following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (22) .
METHODS

Search strategy
We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to identify and select relevant studies Cui X, Kong Y, Jia J. Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: A meta-analysis of randomized trials. Rev Esp Enferm Dig 2015;107:591-597. published up to February 2015. We also scanned the reference lists of relevant reviews and articles, and checked the clinical trial registry for additional studies (clinicaltrials.gov). The following search terms were used: "hepatitis C virus", "hepatitis C", "HCV", "simeprevir", "SMV", "TMC435". No language or publication restrictions were imposed.
Study selection
The following criteria were applied for study inclusion: a) RCTs; b) male or female patients, who had chronic infection with HCV genotype 1; c) SMV administered at any dose and duration; and d) studies that compared SMV plus PegIFN/RBV (triple regimen) with placebo plus PegIFN/RBV (dual regimen).
Exclusion criteria were: a) non-randomized trials; b) non-human studies; c) studies including patients co-infected with human immunodeficiency virus or hepatitis B virus; d) studies with patients who had undergone liver transplantation; and e) duplicate data or publications.
Data extraction
The following information was extracted from each study according to the aforementioned inclusion criteria: a) general characteristics, including first author, published year, geographical area, sample size, median age, gender, dosage and duration of SMV; b) primary outcomes of each RCTs, including the rate of SVR (defined as an undetectable HCV RNA level 12 or 24 weeks post-cessation of treatment) and viral relapse (defined as a detectable HCV RNA level during follow-up or at the time of SVR assessments after achieving undetectable levels at the end of the treatment). Secondary outcomes, including the rate of rapid virologic response (RVR), the incidence of AEs and serious AEs. RVR was defined as undetectable HCV-RNA 4 weeks after treatment initiation. AEs in these included RCTs were defined as occurring in > 25% of the treated patients during the first 12 weeks of treatment and during the entire treatment period. Serious adverse events were referred to AEs which may lead to permanent discontinuation of at least one study drug.
Quality assessment
Two independent assessors (Cui X.H. & Kong Y.Y.) appraised the quality of every trial using a 5-point quality scale, i.e. the Jadad system (23) , which including randomization (0-2 points), double blinding (0-2 points) and the description of withdrawals and dropouts (0 or 1 point). Final scores of 0-2 were deemed as low quality, whereas scores of > 3 were considered as high quality. Any discrepancies between the two assessors were resolved by discussion with a third assessor (Jia J.D.).
Statistical analysis
Dichotomous outcomes were pooled and presented as odds ratio (OR) or relative risk (RR) with a 95% confidence interval (CI). Heterogeneity among the included trials was measured using the Cochran Q test to test for heterogeneity and the I 2 statistic test to quantify the between-study heterogeneity. P Q statistic < 0.1 was deemed statistically significant and I 2 > 50% indicated substantial heterogeneity. With respect to heterogeneous data, a random-effects model was used (24) ; otherwise, a fixed-effects model was used (25) . Finally, potential publication bias was investigated using Begg's funnel plot and Egger's regression test (26, 27) .The meta-analysis was conducted using the Stata/SE software (STATA), version 12.0 (StataCorp LP, College Station, TX, USA). All p values were two-sided and < 0.05 was considered to be statistically significant.
RESULTS
Study characteristics
The database search identified 180 relevant titles and abstracts that potentially could have been included in this meta-analysis. One hundred and sixty-seven studies were excluded after briefly reading the titles and abstracts, and two were excluded after reading the full texts. Ultimately, seven RCTs (28-34) with a total of 2,301 patients were included in our analysis: five enrolled treatment-naïve patients (29) (30) (31) (32) (33) and two treatment-experienced patients (28,34) ( Fig. 1) . The baseline characteristics of the included trials are briefly described in table I. A total of 1,688 patients in the analysis were randomized to the triple regimen and 613 to the dual regimen. The included trials were mainly conducted in North America, Europe and Asia-Pacific regions.
Quality assessment of the studies
The results of the quality assessment of the included studies according to the Jadad system are shown in table II. All the seven included RCTs described briefly the randomization procedure that they had applied. Six of the RCTs used double-blind methods and four of them described the methods appropriately. All the trials stated the number and reasons for patient withdrawal. All seven RCTs (28) (29) (30) (31) (32) (33) (34) were regarded as having good methodological quality and their score ranged from 3 to 5 points.
Quantitative data synthesis
Primary outcome
SVR There was between-study heterogeneity among the seven RCTs (I 2 = 51.0%, P Heterogeneity = 0.057). Thus, the results were pooled using the random-effects model, which indicated that the SVR rate in the triple regimen (1,323/1,688; 78.4%) was significantly higher than that in the dual regimen (289/613; 47.1%), with a pooled OR of 4.57 (95% CI = 3.34-6.27; p < 0.001) ( Fig. 2) . Subgroup analysis according to patients' HCV genotype (1a and 1b), IL28B genotype (CC, CT and TT), META-VIR fibrosis score (F0-2 and F3-4), treatment background (treatment-naïve or treatment-experienced) and administered dosage of SMV (100 or 150 mg) were in accordance with the above results (Table III) .
The SVR rates in the HCV genotype 1a subgroup (OR = 3.72; 95% CI = 2.23-6.19) and 1b subgroup (OR = 6.05; 95% CI = 4.44-8.25) were significantly higher than that of the dual regimen. As regards the IL28B genotype, triple regimen more frequently than dual regimen achieved SVR among in 405 patients with IL28B genotype CC (OR = 5.37; 95% CI = 3.02-9.54), in 831 patients with IL28B genotype CT (OR = 5.93; 95% CI = 4.28-8.21) and in 194 patients with IL28B genotype TT (OR = 5.02; 95% CI = 2.52-10.01). Moreover, SVR was more frequently observed in triple regimen than dual regimen in patients with METAVIR fibrosis score F0-2 (OR = 4.33; 95% CI = 3.32-5.64) and F3-4 (OR = 5.49; 95% CI = 2.66-11.31).The SVR rates in the treatment-naïve patients (OR = 3.71; 95% CI = 2.88-4.79) and treatment-experienced patients (OR = 7.09; 95% CI = 4.89-10.26) were significantly higher than for the dual regimen. Similar results were also found in patients receiving SMV at 100 mg QD (OR = 5.41; 95% CI = 2.78-10.54) and 150 mg QD for 12 weeks (OR = 4.66; 95% CI = 3.43-6.33) (Table III) .
From the results of the subgroup analysis, we concluded that the above-mentioned different stratification factors may have contributed to the heterogeneity in SVR rate.
Relapse rate
The relapse rate for the triple regimen was less frequent than for the dual regimen (RR = 0.41; 95% CI= 0.33-0.50). No between-study heterogeneity was observed among the included studies (I 2 = 38.1%; P Heterogeneity = 0.138) ( Fig. 3) .
Secondary outcome
RVR
Pooling the six trials (28) (29) (30) (32) (33) (34) that had provided RVR rates, the results showed that the RVR rate in the triple regimen (1,146/1,552; 73.8%) was dramatically higher compared with the dual regimen (42/545; 7.7%), with a pooled OR of 43.19 (95% CI = 30.10-61.96; p < 0.001) ( Fig. 4) . 
AEs and serious AEs (SAEs)
Four studies (26, 27, 30, 31) in the meta-analysis stated the numbers of patients with AEs, and the pooled incidence of AEs was comparable in the triple and dual regimens (RR = 1.01; 95% CI = 0.99-1.03). There was no significant between-study heterogeneity in these two regimens (I 2 = 30.5%, P Heterogeneity = 0.229) (Fig. 5) .
The incidence of SAEs for the triple regimen was significantly lower than for the dual regimen (RR= 0.70; 95% CI = 0.50-0.98). There was no significant between-study heterogeneity in these two groups (I 2 = 0.0%, P Heterogeneity = 0.603) (Fig. 5) . 
Publication bias
Begg's funnel plot and Egger's test were performed to assess the potential publication bias in the available literature. The shape of the funnel plots appeared symmetrical. Egger's test also showed no statistical significance for the evaluation of publication bias (p = 0.368).
DISCUSSION
This meta-analysis showed that the SVR and RVR rates in the triple regimen with SMV/PegIFN/RBV were significantly higher than those in the dual regimen with PegIFN/ RBV, both in treatment-naïve and treatment-experienced patients. The relapse rate in patients treated with the triple regimen was lower than the rate in those treated with the dual regimen. The pooled incidence of AEs was similar in the two regimens, and the incidence of SAEs in the triple regimen was lower than that in the dual regimen. We found that the pooled analysis of the SVR rate (I 2 = 51.0%) had between-study heterogeneity, which was mainly due to different stratification factors. However, the results of different subgroup were in accordance with those of the overall population regardless of patients' HCV subtype, IL-28B genotype, the severity of liver fibrosis, treatment background and simeprevir dosage. Therefore, we believe that the addition of SMV to PegIFN/RBV may significantly improve the SVR.
AEs in these included RCTs were clinically manageable and the most common AEs caused by the triple regimen were headache, fatigue, and influenza-like illness; all of which were well-known AEs associated with the dual regimen (28) (29) (30) (31) (32) (33) (34) 35) . Our meta-analysis showed that the pooled incidence of AEs with triple therapy was similar to that with the dual regimen, suggesting that addition of SMV to PegIFN/RBV at least did not exacerbate the AEs of the dual regimen. However, only four trials (28, 29, 32, 33) in our meta-analysis provided the numbers of patients with AEs, and larger clinical studies are still needed to validate the long-term safety and tolerability of the triple regimen in patients with chronic HCV genotype 1 infection.
Surprisingly, the incidence of SAEs with the triple regimen was even lower than that with the dual regimen. By carefully checking the included trials, we found that treatment duration for the triple regimen, which was response-guided (treatment was stopped at week 24 in patients with HCV RNA < 25 IU/mL undetectable or detectable at week 4 and < 25 IU/mL undetectable at week 12; if not, it was continued until week 48, as for patients with the dual regimen) compared with the dual regimen, implying a shorter mean exposure to the dual regimen. This may explain the reduced frequency of SAEs seen with the triple regimen.
There were some limitations in our meta-analysis. First, only seven RCTs were included. Second, there was between-study heterogeneity in SVR rate among the included trials. Finally, most patients in the included trials were white, and nearly all of the patients did not have cirrhosis, therefore our conclusion may have been biased.
In conclusion, SMV in combination with PegIFN/RBV was effective and well-tolerated in the treatment of chronic HCV genotype 1-infected patients. The triple regimen substantially improved the SVR rate and reduced the relapse rate, without worsening the known AEs compared with the dual regimen. However, further studies are needed to investigate the efficacy and safety of SMV in both PegIFN and PegIFN-free combinations, including all oral regimens. Fig. 4 . Forest plot comparing the triple regimen with the dual regimen in terms of the rapid virologic response rate. Fig. 5 . Forest plot comparing the triple regimen with the dual regimen in terms of the incidence of adverse events and serious adverse events (AEs: Adverse events; SAEs: Serious adverse events).
